GO:0055104 ligase inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0055104 ligase inhibitor activity describes a molecular function where a protein or small molecule binds to and reduces the activity of a ligase enzyme.
• This activity is critical for regulating ubiquitination, DNA repair, and cell signaling, with direct implications for cancer, immunity, and neurodegeneration.
• Key proteins with ligase inhibitor activity include Smac/Diablo, which antagonizes inhibitor of apoptosis (IAP) ubiquitin ligases, and small-molecule inhibitors of DNA ligase I.
• Dysregulation of ligase inhibitor activity contributes to chemotherapy resistance, inflammatory diseases, and impaired protein production in bioprocessing.
• CRISPR-based knockout, point mutation, and knock-in models are essential to dissect the causal roles of ligase inhibitor activity in disease and to validate therapeutic targets.
• EDITGENE provides end-to-end services for generating and screening custom cell models to study ligase inhibitor activity and its interacting partners.
Description
Ligase inhibitor activity (GO:0055104) is a molecular function defined as the binding to and stopping, preventing, or reducing the activity of a ligase enzyme. Ligases are fundamental to cellular processes such as DNA replication and repair, protein ubiquitination, and signal transduction. By modulating ligase activity, inhibitor proteins and small molecules serve as critical regulators of these pathways, ensuring proper cellular homeostasis. The study of ligase inhibitor activity has revealed its importance in diverse biological contexts, from immune responses in rice to cancer therapy resistance in humans. Understanding this activity is therefore essential for both basic research and therapeutic development.
ligase inhibitor activity At A Glance
| GO ID | GO:0055104 |
|---|---|
| GO term | ligase inhibitor activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binds to and stops, prevents or reduces the activity of a ligase |
| Related ligases | Ubiquitin ligases, DNA ligases, SUMO ligases |
| Biological context | Regulation of protein degradation, DNA repair, immune signaling |
| Disease relevance | Cancer, neurodegeneration, inflammatory diseases |
| Experimental approaches | CRISPR KO, point mutation, knock-in, overexpression, small-molecule screening |
What Is GO:0055104?
According to the Gene Ontology, ligase inhibitor activity (GO:0055104) is a molecular function that encompasses any protein or molecule that binds to a ligase and reduces its enzymatic activity. This inhibition can be competitive, uncompetitive, or non-competitive, and it serves as a key regulatory mechanism in pathways where ligase activity must be tightly controlled. The term is distinct from other inhibitor activities because it specifically targets ligases, enzymes that catalyze the joining of two molecules with concomitant hydrolysis of ATP or a similar triphosphate.
Why Is ligase inhibitor activity Important in Cell Biology?
Ligase inhibitor activity is a fundamental regulatory mechanism that controls the timing and extent of ligase-mediated processes. For example, Smac/Diablo antagonizes the ubiquitin ligase activity of inhibitor of apoptosis proteins (IAPs), thereby promoting apoptosis and influencing cancer cell survival. Small-molecule inhibitors of DNA ligase I have been characterized for their potential to sensitize cancer cells to DNA-damaging agents. Furthermore, inhibition of ubiquitin ligase activity can enhance the production of biologically active fusion proteins in biotechnological applications. Thus, understanding ligase inhibitor activity is crucial for developing targeted therapies and improving bioprocesses.
• Regulates ubiquitin-proteasome system by inhibiting E3 ubiquitin ligases, affecting protein turnover.
• Modulates DNA repair pathways through inhibition of DNA ligases, with implications for cancer therapy.
• Controls immune signaling, as shown by the release of a ubiquitin brake on OsCERK1 in rice immunity.
• Influences inflammatory responses by mitigating STING-induced inflammation via Parkin and PINK1.
• Contributes to chemotherapy resistance, e.g., PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer.
• Enhances recombinant protein production by inhibiting ubiquitin ligase activity in CHO cells.
• Provides targets for small-molecule inhibitor discovery, such as Mdm2 ubiquitin ligase inhibitors.
• Plays a role in metabolic regulation through ACSL family enzymes and their inhibitors.
• Offers a mechanism to fine-tune ligase-dependent signaling pathways in development and disease.
• Enables precise control of gene editing outcomes by modulating DNA ligase IV activity in CRISPR applications.
Molecular Mechanism of ligase inhibitor activity
Binding to the Ligase
In simple terms: The inhibitor molecule attaches to the ligase enzyme.
The first step in ligase inhibitor activity is the physical binding of the inhibitor to the ligase. This interaction can occur at the active site, an allosteric site, or an interface required for ligase function. For example, Smac/Diablo binds to IAPs and antagonizes their ubiquitin ligase activity. Small-molecule inhibitors of DNA ligase I have been shown to bind selectively and uncompetitively, suggesting interaction with the enzyme-substrate complex.
Inhibition of Catalysis
In simple terms: The inhibitor stops the ligase from doing its job.
Once bound, the inhibitor prevents the ligase from catalyzing the joining of molecules. This can be achieved by blocking the active site, inducing conformational changes, or preventing essential cofactor binding. For ubiquitin ligases, inhibition can prevent the transfer of ubiquitin to target proteins, thereby stabilizing substrates. In the case of DNA ligase I, uncompetitive inhibition reduces the rate of phosphodiester bond formation.
Regulation by Protein-Protein Interactions
In simple terms: Other proteins can control whether the inhibitor works.
Ligase inhibitor activity is often regulated by upstream signals that control the availability or activity of the inhibitor. For instance, the release of a ubiquitin brake on OsCERK1 in rice involves the degradation of an inhibitor, thereby activating the ligase. Similarly, Parkin and PINK1 mitigate STING-induced inflammation by modulating ubiquitin ligase activity. These examples highlight the dynamic nature of ligase inhibitor regulation.
Small-Molecule Inhibitors
In simple terms: Drug-like molecules can also inhibit ligases.
Beyond proteins, small molecules can exhibit ligase inhibitor activity. Quantitative assays have been developed to discover inhibitors of Mdm2 ubiquitin ligase activity. Selective uncompetitive inhibitors of DNA ligase I have been characterized, providing tools to probe DNA repair. These small molecules offer potential therapeutic avenues, especially in cancer where ligase overexpression or dysregulation occurs.
Physiological Consequences
In simple terms: Inhibiting a ligase changes cell behavior.
The inhibition of ligase activity can have profound effects on cellular processes. For example, inhibiting ubiquitin ligase activity can enhance the production of biologically active fusion proteins in CHO cells. In cancer, PTEN neddylation aggravates CDK4/6 inhibitor resistance, implicating ligase inhibitor activity in therapy response. Thus, ligase inhibitor activity is a key node in cellular decision-making.
Key Genes Involved in GO:0055104 ligase inhibitor activity
The following genes and proteins are directly implicated in ligase inhibitor activity or serve as key ligases whose inhibition is studied.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DIABLO (Smac/Diablo) | Antagonizes IAP ubiquitin ligases | Promotes apoptosis; cancer therapy target |
| XIAP | Ubiquitin ligase inhibited by Smac/Diablo | Inhibitor of apoptosis; cancer and neurodegeneration |
| LIG1 | DNA ligase I; inhibited by small molecules | DNA repair; cancer chemotherapy sensitization |
| MDM2 | Ubiquitin ligase; target of inhibitor discovery | p53 regulation; cancer |
| PTEN | Neddylation target; affects CDK4/6 inhibitor resistance | Breast cancer therapy resistance |
| PARK2 (Parkin) | E3 ubiquitin ligase; mitigates STING inflammation | Neurodegeneration; inflammation |
| PINK1 | Kinase that activates Parkin | Mitophagy; neurodegeneration |
| OSCERK1 | Rice receptor kinase; regulated by ubiquitin brake | Plant immunity |
| ACSL1 | Long-chain acyl-CoA synthetase; ligase family | Cancer metabolism; inhibitor development |
| ACSL3 | Long-chain acyl-CoA synthetase | Cancer metabolism |
| ACSL4 | Long-chain acyl-CoA synthetase | Cancer metabolism; ferroptosis |
| ACSL5 | Long-chain acyl-CoA synthetase | Cancer metabolism |
| ACSL6 | Long-chain acyl-CoA synthetase | Cancer metabolism |
| STING1 | Stimulator of interferon genes; regulated by Parkin/PINK1 | Inflammation; immunity |
| CDK4 | Cyclin-dependent kinase 4; affected by PTEN neddylation | Breast cancer resistance |
| CDK6 | Cyclin-dependent kinase 6; affected by PTEN neddylation | Breast cancer resistance |
| HSA-HGF | Fusion protein; production enhanced by ligase inhibition | Biotechnological production |
How Is ligase inhibitor activity Regulated?
Ligase inhibitor activity is regulated at multiple levels. The expression and stability of inhibitor proteins can be controlled by transcription, translation, and degradation. For example, the release of a ubiquitin brake on OsCERK1 involves the degradation of an inhibitor, thereby activating the ligase. Post-translational modifications, such as phosphorylation and ubiquitination, can modulate the interaction between inhibitors and ligases. In the case of Parkin and PINK1, PINK1 phosphorylates Parkin to activate its ligase activity, which is then balanced by inhibitors. Additionally, small-molecule inhibitors can be developed to exogenously regulate ligase activity, as shown for Mdm2 and DNA ligase I. These regulatory mechanisms ensure that ligase inhibitor activity is finely tuned to cellular needs.
ligase inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DIABLO | Cancer (apoptosis evasion) | Knockout and overexpression in cancer cell lines |
| LIG1 | Cancer (DNA repair) | Point mutation of catalytic residues; inhibitor treatment |
| MDM2 | Cancer (p53 inactivation) | Knock-in of inhibitor-resistant mutants |
| PTEN | Breast cancer (CDK4/6 inhibitor resistance) | Knockout and neddylation-site mutants |
| PARK2 | Parkinson's disease (mitophagy) | Knockout and point mutation in neurons |
Cancer
Ligase inhibitor activity is deeply implicated in cancer. Smac/Diablo antagonizes IAP ubiquitin ligases, promoting apoptosis and serving as a tumor suppressor mechanism. Small-molecule inhibitors of DNA ligase I have been explored to sensitize cancer cells to DNA-damaging therapies. Mdm2 ubiquitin ligase inhibitors are pursued for p53 activation in tumors. PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer, highlighting how ligase inhibitor activity can influence therapy response. Thus, targeting ligase inhibitor activity is a promising anticancer strategy.
Neurodegeneration
Parkin and PINK1 mitigate STING-induced inflammation, linking ligase inhibitor activity to neuroinflammation and neurodegeneration. Loss of Parkin or PINK1 function leads to impaired mitophagy and increased inflammation, contributing to Parkinson's disease. Modulating ligase inhibitor activity may offer therapeutic avenues for neurodegenerative disorders.
Inflammatory and Immune Disorders
The release of a ubiquitin brake on OsCERK1 in rice immunity demonstrates the role of ligase inhibitor activity in plant immune signaling. In mammals, STING-induced inflammation is mitigated by Parkin and PINK1, suggesting that ligase inhibitor activity is crucial for preventing excessive immune responses. Dysregulation can lead to autoimmune or inflammatory diseases.
Metabolic Disorders and Bioprocessing
ACSL family enzymes are ligases involved in fatty acid metabolism, and their inhibitors have therapeutic implications in cancer and metabolic diseases. Inhibition of ubiquitin ligase activity improves the production of biologically active fusion proteins in CHO cells, relevant for biopharmaceutical manufacturing.
From ligase inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a ligase inhibitor affect apoptosis? | CRISPR knockout of DIABLO in cancer cells |
| Can a point mutation in LIG1 confer inhibitor resistance? | CRISPR point mutation at catalytic residues |
| How does PTEN neddylation influence drug resistance? | Knock-in of neddylation-deficient PTEN |
| What is the role of Parkin ligase activity in inflammation? | Knockout and tagged knock-in of PARK2 |
| Can overexpression of Smac/Diablo sensitize tumors? | Overexpression of DIABLO in xenografts |
| Does inhibition of ubiquitin ligase improve protein production? | Knockout of specific E3 ligases in CHO cells |
How to Study the ligase inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ubiquitination assay | Ligase activity and inhibition | Screening for Mdm2 inhibitors |
| DNA ligation assay | Ligase I activity and inhibition | Characterizing selective inhibitors |
| CRISPR knockout screen | Gene essentiality and modifier identification | Discovering ligase inhibitor genes |
| Co-immunoprecipitation | Protein-protein interactions | Detecting Smac/Diablo-IAP binding |
| Mass spectrometry | Protein identification and modifications | Mapping neddylation of PTEN |
| Reporter assays | Pathway activity (e.g., STING, NF-kB) | Assessing inflammation modulation |
| Flow cytometry | Apoptosis and cell survival | Evaluating Smac mimetics |
| Protein production assays | Yield of biologically active fusion proteins | Optimizing CHO cell bioprocesses |
Quantitative Assays for Ligase Inhibitor Activity
Quantitative assays are essential to measure ligase inhibitor activity. For ubiquitin ligases, assays often monitor the transfer of ubiquitin to substrates using fluorescence or luminescence. For DNA ligases, gel-based or fluorescence-based assays can detect ligation products and their inhibition. These methods enable high-throughput screening for small-molecule inhibitors.
CRISPR Screening and Functional Genomics
CRISPR knockout and activation screens can identify genes that modulate ligase inhibitor activity. For example, genome-wide screens can uncover inhibitors of ubiquitin ligases or DNA ligases. Such screens are powerful for discovering new components of ligase regulatory networks.
Proteomics and Interactomics
Mass spectrometry-based proteomics can identify proteins that interact with ligases and inhibit their activity. Affinity purification followed by mass spectrometry can reveal inhibitor-ligase complexes, as demonstrated for Smac/Diablo and IAPs. These approaches provide mechanistic insights.
Structural Biology and Modeling
X-ray crystallography and cryo-EM can elucidate the structural basis of ligase inhibition. For instance, the structure of DNA ligase I with an uncompetitive inhibitor revealed key binding determinants. Computational docking can predict new inhibitors.
How CRISPR Can Be Used to Study GO:0055104 ligase inhibitor activity
Knockout
CRISPR knockout of genes encoding ligase inhibitors or ligases themselves can reveal their roles in cellular processes. For example, knocking out DIABLO (Smac/Diablo) would increase IAP ubiquitin ligase activity, affecting apoptosis. Knocking out LIG1 can sensitize cells to DNA damage. These models are crucial for target validation.
Point Mutation
Point mutations can be introduced to disrupt specific catalytic residues or binding interfaces. For instance, mutating the catalytic cysteine of a ubiquitin ligase can abolish its activity, mimicking inhibition. Point mutations in PTEN at neddylation sites can prevent neddylation and alter drug resistance. Such models provide mechanistic insights.
Knock-in
Knock-in of tagged or mutant versions of ligases or inhibitors allows precise tracking and functional analysis. For example, knocking in a fluorescently tagged PARK2 can monitor its localization and interactions. Knock-in of inhibitor-resistant ligase mutants can test the specificity of inhibitors.
Overexpression
Overexpression of ligase inhibitors can suppress ligase activity and phenocopy inhibition. Overexpressing DIABLO can promote apoptosis in cancer cells. Overexpressing a dominant-negative ligase can also mimic inhibition. These models are useful for gain-of-function studies.
How EDITGENE Supports ligase inhibitor activity Research
Researchers studying ligase inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in a specific pathway or disease. EDITGENE provides custom CRISPR cell models and screening services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for ligase inhibitor activity research.
Frequently Asked Questions About ligase inhibitor activity
What is ligase inhibitor activity?
Ligase inhibitor activity (GO:0055104) is a molecular function where a protein or small molecule binds to and reduces the activity of a ligase enzyme, thereby regulating processes like ubiquitination and DNA repair.
What genes are involved in ligase inhibitor activity?
Key genes include DIABLO (Smac/Diablo), XIAP, LIG1, MDM2, PTEN, PARK2, PINK1, and ACSL family members, all of which modulate or are modulated by ligase inhibitor activity.
How does ligase inhibitor activity affect cancer?
It influences apoptosis, DNA repair, and drug resistance. For example, Smac/Diablo inhibits IAP ubiquitin ligases to promote apoptosis, while PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer.
What are examples of ligase inhibitors?
Smac/Diablo is a protein inhibitor of IAP ubiquitin ligases, and small molecules like selective uncompetitive DNA ligase I inhibitors have been characterized.
How can I study ligase inhibitor activity in the lab?
Common methods include ubiquitination assays, DNA ligation assays, CRISPR knockout screens, co-immunoprecipitation, and mass spectrometry.
What is the role of ligase inhibitor activity in neurodegeneration?
Parkin and PINK1 mitigate STING-induced inflammation, and their ligase activities are critical for mitophagy; dysregulation contributes to Parkinson's disease.
Can CRISPR be used to model ligase inhibitor activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes involved in ligase inhibitor activity.
What diseases are linked to ligase inhibitor activity?
Cancer, neurodegeneration, inflammatory disorders, and metabolic diseases are linked to dysregulated ligase inhibitor activity.
How does ligase inhibitor activity affect protein production?
Inhibition of ubiquitin ligase activity can improve the production of biologically active fusion proteins in CHO cells.
What services does EDITGENE offer for ligase inhibitor research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services to study ligase inhibitor activity.
Conclusion
Ligase inhibitor activity (GO:0055104) is a pivotal molecular function that regulates diverse cellular processes by controlling ligase enzymes. Its roles in apoptosis, DNA repair, immunity, and metabolism underscore its importance in health and disease. Advances in CRISPR-based models and screening technologies are accelerating our understanding of this activity and its therapeutic potential. EDITGENE stands ready to support researchers with custom cell models and services to explore ligase inhibitor activity in depth.
References
- 1. Wang G et al.. 2024. Release of a ubiquitin brake activates OsCERK1-triggered immunity in rice.. Nature 629(8014):1158-1164 PMID: 38750355
- 2. Sliter DA et al.. 2018. Parkin and PINK1 mitigate STING-induced inflammation.. Nature 561(7722):258-262 PMID: 30135585
- 3. Quan J et al.. 2021. ACSL family: The regulatory mechanisms and therapeutic implications in cancer.. Eur J Pharmacol 909:174397 PMID: 34332918
- 4. Creagh EM et al.. 2004. Smac/Diablo antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins.. J Biol Chem 279(26):26906-14 PMID: 15078891
- 5. Howes TRL et al.. 2017. Structure-activity relationships among DNA ligase inhibitors: Characterization of a selective uncompetitive DNA ligase I inhibitor.. DNA Repair (Amst) 60:29-39 PMID: 29078112
- 6. Auger KR et al.. 2005. Quantitative assays of Mdm2 ubiquitin ligase activity and other ubiquitin-utilizing enzymes for inhibitor discovery.. Methods Enzymol 399:701-17 PMID: 16338390
- 7. Liu F et al.. 2025. PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer.. Oncogene 44(33):2997-3013 PMID: 40533484
- 8. Xu D et al.. 2017. Inhibition of the ubiquitin ligase activity improves the production of biologically active fusion protein HSA-HGF in Chinese hamster ovary cells.. Bioengineered 8(3):256-264 PMID: 27753513
